Tunable Quantitative Assays


Invention Summary:

Traditional hybridization-based methods used single stranded probes (P) complementary to single stranded target sequences (T). Such approaches frequently lacked the stringency to differentiate between P-T perfect matches (primary “hits”) and energetically similar yet imperfect P-M mismatches (secondary “hits”), thereby resulting in false positives that compromise many applications. Scientists at Rutgers have designed a way to simultaneously quantitate target biomarkers and discriminate these biomarkers from closely related molecular entities.  By making use of the thermodynamics of competitive differential hybridization, Tunable Quantitation Assays (TQAs) quantify target concentrations and substantially reduce the occurrence of false positives. This technology allows the target binding affinity to be rationally modulated to create useful signal ranges optimized for a given diagnostic platform. TQA technology is applicable to a wide variety of previously developed biosensor and diagnostic platforms.

Market Application:

  • Diagnostics
  • Bioinformatics
  • Microfluidics
  • RT-PCR
  • Biosensors

Advantages:

  • Reduces false positives in existing technologies
  • Works for both DNA-meter and Apta-meter (protein, small molecules, etc.) diagnostics
  • Complementary to fluorescence technologies

Intellectual Property & Development Status:

Patent issued. Available for licensing and/or research collaboration.

Select Publications:

  • Braunlin, WH et al. 2013. DNA Meter: Energy Tunable Quantitative Hybridization Assay. Biopolymers, 99:408-417.
  • Völker J, et al. 2010. Energy crosstalk between DNA lesions: implications for allosteric coupling of DNA repair and triplet repeat expansion pathways. J Am Chem Soc. 132(12):4095-7.
  • Völker  J, et al. 2010. Energetic coupling between clustered lesions modulated by intervening triplet repeat bulge loops: Allosteric implications for DNA repair and triplet repeat expansion. Biopolymers.  93(4):355-69.
Patent Information:
Licensing Manager:
Lisa Lyu
Assistant Director
Rutgers, The State University of New Jersey
848-932-4539
lisa.lyu@rutgers.edu
Business Development:
Eusebio Pires
Senior Manager, Technology Marketing & Business Development
Rutgers, The State University of New Jersey
ep620@research.rutgers.edu
Keywords:
Biomaterials
Drug Delivery
Inflammation
Neurological disorder & neuropathic pain